GB1565657A - Combined vaccines against rubella and cutomegalic inclusion disease - Google Patents
Combined vaccines against rubella and cutomegalic inclusion disease Download PDFInfo
- Publication number
- GB1565657A GB1565657A GB3393576A GB3393576A GB1565657A GB 1565657 A GB1565657 A GB 1565657A GB 3393576 A GB3393576 A GB 3393576A GB 3393576 A GB3393576 A GB 3393576A GB 1565657 A GB1565657 A GB 1565657A
- Authority
- GB
- United Kingdom
- Prior art keywords
- strain
- rubella
- vaccine
- cmv
- vaccinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/20—Rubella virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36211—Rubivirus, e.g. rubella virus
- C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
(54) COMBINED VACCINES AGAINST RUBELLA AND
CYTOMEGALIC INCLUSION DISEASE
(71) We, RECHERCHE ET INDUSTRIE
THERAPEUTIQUES, RIT, of 13 rue du Tilleul,
B-320 Genval, Belgium, a Belgian Body Corporate do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:
This invention related to bivalent vaccines against rubella and cytomegalic inclusion disease (CMID).
Rubella virus is known to pass through the human placenta and to infect the foetus, and it can cause severe anomalies in new-born children.
Maternal circulatory antibodies against rubella virus can prevent this threat, and for many years different vaccines have been developed either as monovalent vaccines or as combined preparations with measles and/or mumps vaccines.
Examples of attenuated vaccines against
rubella are vaccines containing the RA 27/3
strain, the HPV 77 DES strain, or the
CENDEHILL strain.
However, rubella virus is not the only virus
which is able to cause damage to the foetus.
Cytomegalovirus (CMV), which causes cyto
megalic inclusion disease, is the most common
cause of both mental retardation and neonatal
microcephaly of viral origin, and it is estimated
that among new-born children excreting this
virus (i.e. from 1 to 4% of all new-born
children), from 5 to 15% present character
istics of mental retardation and that from 30
to 45% of nubile women do not have anti
bodies against CMV.
This is the reason why, in several countries,
investigators have been studying the innocuity
and efficacy of vaccines against CMID.
Examples of virus strains used in these vaccines are the TOWNE 125 strain (Just. M., et al., Infection 3: 111-14, 1975) and a vaccinal strain derived from the Ad 169 strain (Elek S.D. et al.: The Lancet 1 (7845): 1-5, 1974). As both rubella virus vaccine and CMV vaccine have the same objective, i.e. protection of the foetus, and as inoculation with both vaccines is by the same route, it seems attractive to inoculate simultaneously both vaccines in the form of a combined vaccine and more particularly in the form of a live combined vaccine.
Furthermore, the use of combined vaccines requires less qualified medical staff and fewer injections than monovalent vaccines.
Interference between CMV and viruses such as myxoviruses, arboviruses, picornaviruses, herpes viruses and poxviruses has been demonstrated by in vitro experiments (Glasgow L.A.,
Infection and Immunity 9: 702-7, April 1974).
Similarly, rubella virus induces in vitro interference with heterologous viruses, e.g.
picornaviruses, myxoviruses and arboviruses (Parkman P.D., et al., J. Immunol 93 (4): 595-607, 1964).
In the study of combined vaccines, preliminary tests are thus needed to determine the possible interference factor in any combination of vaccines. We have found that in a combined live vaccine against rubella and
CMID, simultaneous administration of both viruses does not affect the immunogenic response to each vaccine component.
According to the present invention there is provided a live combined vaccine against rubella and cytomegalic inclusion disease, in dosage unit form, comprising respective amount of vaccinal rubella virus and of vaccinal cytome galovirus corresponding at least to the immunogenic amounts of each virus. The attenuated viruses can be cultivated separately according to processes known to the art and mixed in adequate ratios, and the obtained bivalent vaccine is preferably freeze-dried after having been supplemented with a stabilizing composition as it is well known to the art. Examples of stabilizing compositions are those containing human serum albumin or polyvinylpyrrolidone.
As CMV is more labile in vitro than rubella virus, the operative conditions for the freezedrying of the bivalent vaccine are those required for the freezedrying of CMV.
As indicated above, the rubella virus strain, preferably in an amount of at least 103 TCIDso per dosage unit can be any vaccinal strain known to the art, e.g. the attenuated
CENDHILL strain cultivated on primary rabbit kidney cell cultures, and the CMV strain, preferably present in an amount of at least 104 TCID50 , can be any vaccinal strain known to the art, e.g. the attenuated TOWNE 125 strain cultivated on human diploid cell line
WI-38.
When bivalent vaccines according to the present invention are freeze-dried, they can be reconstituted by the addition of either water or any other diluent for the preparation of parenteral vaccines.
The so-obtained bivalent vaccines of the present invention can be administered intramuscularly or subcutaneously.
The following Examples illustrate the present invention.
EXAMPLE 1
To 375 ml. of the supernatant of a WI-38 cell culture containing about 1047TCIDso of CMV, TOWNE 125 strain, per millilitre is added the same volume of an aqueous solution containing sucrose (0.218 M), potassium monobasic phosphate (0.0038 M), sodium dibasic phosphate (0.0072 M), potassium glutamate (0.0049 M) and sodium ethylenediamine tetraacetate (EDTA) (0.2%) supplemented with human serum albumin (1%).
To 125 ml of the supernatant of a primary rabbit kidney cell culture containing about 103OTCID50 of rubella virus, CENDEHILL strain, per millilitre is added the same volume of an aqueous solution containing sucrose (200 gll.) and potassium glutamate (30 g/l.).
Both preparations are thoroughly mixed and the mixture is distributed into glass vials containing each one millilitre of combined vaccine in order to obtain dosage units administrable by intramuscular or subcutaneous routes.
Vaccination of 13 adults susceptible to both viruses demonstrated formation of antibodies against rubella virus, -demonstrated by hemagglutination inhibition test, and against CMVdetermined by immunofluorescense assay, from 6 to 8 weeks after vaccination.
EXAMPLE 2
To 270 ml. of the supernatant of a WI-38 cell culture containing about 104-8TCIDso of CMV, TOWNE 125 strain, per millilitre is added the same volume of an aqueous solution of sucrose (0.218 M), potassium monobasic phosphate (0.0038 M), sodium dibasic phosphate (0.0072 M), potassium glutamate (0.0049 M) and sodium EDTA (0 2to) supplemented with human serum albumin (loo) To 90 ml of the supernatant of a primary rabbit kidney cell culture containing about 104 3TCIDso per ml. of rubella virus,
CENDEHILL strain, is added the same volume of an aqueous solution of sucrose (200 girl.) and potassium glutamate (30 girl.).
Both preparations are mixed and the mixture is distributed into glass vials, each containing one millilitre of combined vaccine which is then freeze-dried. The vials are then tightly stoppered.
The titres per dosage unit after freeze-drying of the bivalent vaccine are 104TCIDso and 1032TCIDso for CMV and the rubella virus respectively.
The vaccine can be administered by the intramuscular or subcutaneous route.
WHAT WE CLAIM IS:
1. A live combined vaccine against rubella and cytomegalic inclusion disease, in dosage unit form, comprising respective amounts of vaccinal rubella virus and vaccinal cytomegalicous corresponding at least to the immunogenic amounts of each virus considered separately.
2. A live combined vaccine against rubella and cytomegalic inclusion disease. in dosage unit form, comprising at least 103TCIDso of vaccinal rubella virus and at least 104TCIDso of vaccinal cytomegalovirus.
3. A live combined vaccine against rubella and cytomegalic inclusion disease according to claim 1 or claim 2, wherein the vaccine has been freeze-dried and it also includes a stabilizing composition for the viruses.
4. A live combined vaccine against rubella and cytomegalic inclusion disease according to any of claims 1 to 3, wherein the attenuated cytomegalovirus is the cytomegalovirus
TOWNE 125 strain.
5. A live combined vaccine against rubella and cytomegalic inclusion disease, the vaccine being substantially as herein described in any of the Examples.
**WARNING** end of DESC field may overlap start of CLMS **.
Claims (5)
1. A live combined vaccine against rubella and cytomegalic inclusion disease, in dosage unit form, comprising respective amounts of vaccinal rubella virus and vaccinal cytomegalicous corresponding at least to the immunogenic amounts of each virus considered separately.
2. A live combined vaccine against rubella and cytomegalic inclusion disease. in dosage unit form, comprising at least 103TCIDso of vaccinal rubella virus and at least 104TCIDso of vaccinal cytomegalovirus.
3. A live combined vaccine against rubella and cytomegalic inclusion disease according to claim 1 or claim 2, wherein the vaccine has been freeze-dried and it also includes a stabilizing composition for the viruses.
4. A live combined vaccine against rubella and cytomegalic inclusion disease according to any of claims 1 to 3, wherein the attenuated cytomegalovirus is the cytomegalovirus
TOWNE 125 strain.
5. A live combined vaccine against rubella and cytomegalic inclusion disease, the vaccine being substantially as herein described in any of the Examples.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB3393576A GB1565657A (en) | 1976-08-16 | 1976-08-16 | Combined vaccines against rubella and cutomegalic inclusion disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB3393576A GB1565657A (en) | 1976-08-16 | 1976-08-16 | Combined vaccines against rubella and cutomegalic inclusion disease |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1565657A true GB1565657A (en) | 1980-04-23 |
Family
ID=10359298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB3393576A Expired GB1565657A (en) | 1976-08-16 | 1976-08-16 | Combined vaccines against rubella and cutomegalic inclusion disease |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB1565657A (en) |
-
1976
- 1976-08-16 GB GB3393576A patent/GB1565657A/en not_active Expired
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4341763A (en) | Methods of vaccinating humans against rotavirus infection | |
Asano et al. | Soluble skin test antigen of varicella-zoster virus prepared from the fluid of infected cultures | |
EP0048201B1 (en) | Herpes simplex type i fraction vaccine and process for its preparation | |
CA1045546A (en) | Highly attenuated cytomegalovirus vaccine and production thereof | |
US4132775A (en) | Infectious bovine rhinotracheitis virus vaccine and method of preparing and using the same | |
US3927208A (en) | Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them | |
Lennette et al. | Neutralization tests with certain neurotropic viruses: A comparison of the sensitivity of the extraneural and intracerebral routes of inoculation for the detection of antibodies | |
US4315914A (en) | Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof | |
Hearn Jr | A variant of Venezuelan equine encephalomyelitis virus attenuated for mice and monkeys | |
Rudd et al. | Intranasal Infection of Mice with the Virus of Psittacosis. | |
CA1039651A (en) | Attenuation of cytomegalovirus | |
EP0650734A1 (en) | Polyvalent live varal vaccine | |
le Q Darcel et al. | Recovery of infectious bovine rhinotracheitis virus following corticosteroid treatment of vaccinated animals. | |
GB1565657A (en) | Combined vaccines against rubella and cutomegalic inclusion disease | |
Zygraich et al. | In vivo behaviour of a temperature-sensitive (ts) mutant of herpesvirus hominis type 2 | |
FR2693472B1 (en) | Mutants of the infectious bovine rhinotracheitis virus, deleted in one of the genes of minor glycoproteins, vaccines prepared from these strains, production methods and methods of use. | |
Marshall et al. | Passively administered neutralizing monoclonal antibodies do not protect calves against bovine herpesvirus 1 infection | |
US4215107A (en) | Parainfluenza virus vaccine and its preparation | |
Norrby et al. | Measles vaccination IV. Responses to two different types of preparations given as a fourth dose of vaccine | |
US3897549A (en) | Herpes simplex type 2 virus vaccine and method of production and use | |
Castrucci et al. | Immunization against bovine herpesvirus-1 infection. Preliminary tests in calves with a DNA vaccine | |
Lee et al. | Humoral immune responses to inactivated oil-emulsified Marek's disease vaccine | |
Haefelin et al. | Effective antiviral prophylaxis and therapy by systemic application of human interferon in immunosuppressed monkeys | |
US4540669A (en) | Herpes simplex type I subunit vaccine | |
EP0661059B1 (en) | An intranasal bovine trivalent vaccine containing modified live IBRV, PI3V and BRSV |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed | ||
PCNP | Patent ceased through non-payment of renewal fee |